SB-224289 was originally developed by SmithKline, now known as GlaxoSmithKline. It was identified as an antagonist of the 5-hydroxytryptamine receptor 1B (5-HT1B) and subsequently investigated for potential antidepressant activity, although no human trials have been reported. Interestingly, SB-224289 was also found to exhibit antagonistic activity for the antifungal mechanism of Marine Depsipeptide Papuamide A in Candida albicans; although the specific mechanism of action remains unknown.

3,4,5-Trimethoxybenzoic acid was used as internal standard during the determination of the various types of hydroxyl groups present in lignins. 3,4,5-Trimethoxybenzoic Acid is a metabolite of trimebutine. It is widely used in making dyes and inks, photographic developers and used as astringents in medically.

Pamoic acid, also called embonic acid, is a naphthoic acid derivative, used as a counter ion of a drug compound to increase the solubility of the drug in water. Pamoic acid has agonist activity for the orphan G protein-coupled receptor GPR35 by which it activates ERK and beta-arrestin2, and causes antinociceptive activity. Although (like other drug salts) it has been considered an inactive compound by the FDA.